Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

Altamira Therapeutics Ltd. recently announced it has entered into a collaboration agreement with a company in the radiopharmaceutical sector to evaluate the use of the company’s proprietary RNA delivery platform for radiopharmaceutical targeting.

Radiopharmaceutical therapy uses tiny amounts of radioactive compounds (“radiopharmaceuticals” or “radioligands”) to diagnose and treat various diseases, in particular cancer. Once injected into the patient, the radiopharmaceutical finds its way to the tumor through the bloodstream and binds to a tumor-specific receptor. The global radiopharmaceutical market reached $8.4 billion in size in 2024 and is expected to grow to US$ 17.1 billion by 2033.

Under the terms of the agreement, Altamira and its project collaboration partner intend to test in vitro and in vivo the use of nanoparticles with an undisclosed RNA payload in conjunction with one of the partner’s proprietary radiopharmaceuticals. Upon successful conclusion of the experiments, the partner will, under certain conditions, have the option to negotiate with Altamira a license and supply agreement to develop and commercialize the RNA nanoparticles for use in cancer treatment.

“We are very delighted to initiate this collaboration to explore the utility of our RNA delivery technology in conjunction with radiopharmaceuticals”, commented Thomas Meyer, PhD, Altamira’s founder, Chairman and Chief Executive Officer. “The concept of radiopharmaceutical therapy has allowed for highly impressive advances in treatment outcomes and holds great promise for expanding precision oncology to additional tumor types. We look forward to working with our partner, on further enhancing radiopharmaceuticals’ therapeutic benefits.”

Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore platform). The company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio, an OTC nasal spray for allergic rhinitis. Further, the company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit https://altamiratherapeutics.com/.